Sweden's SciBase Q4 sales rise on US, skin barrier growth

Reuters
03/13
Sweden's SciBase Q4 sales rise on US, skin barrier growth

Overview

  • Sweden medical technology firm's Q4 net sales rose 45% yr/yr, loss after tax widened

  • Gross margin fell to 63% from 68.5%, impacted by currency and higher input costs

Outlook

  • Company did not provide specific financial or operational guidance for the future in its press release

Result Drivers

  • ELECTRODE SALES - Electrode sales volume rose 67% in Q4, with repeat sales to existing customers up 48%

  • GROSS MARGIN PRESSURE - Gross margin was negatively affected by currency, higher gold prices, initial delivery to Castle Biosciences, and increased production investments

  • US AND SKIN BARRIER GROWTH - US skin cancer sales rose 84% (106% in local currency), and skin barrier segment sales surged 294%

Company press release: ID:nWkr5bvdrp

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

SEK 12.48 mln

Q4 EPS

-SEK 0.06

Q4 Net Income

-SEK 25.30 mln

Q4 Gross Margin

63.00%

Analyst Coverage

  • Wall Street's median 12-month price target for SciBase Holding AB (publ) is SEK0.50, about 79.9% above its March 12 closing price of SEK0.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10